Eli Lilly's release of Zepbound in a single-dose glass vial allows for increased supply and reduced costs, making weight-loss treatment more accessible despite a less convenient delivery method.
The new single-dose vials will allow Eli Lilly to increase supply and drop the price to $99.75 per vial, a considerable reduction from the roughly $1,000 for Zepbound or other weight-loss drugs.
Patrik Jonsson, Lilly USA president, stated that this design change will not only address high demand for obesity medicine but will also broaden patient access to effective treatments.
While the single-dose vial is a more cost-effective solution, studies indicate that prefilled insulin pens are preferred for their ease of use and handling, highlighting a trade-off in user experience.
Collection
[
|
...
]